Dr. Alexey V. Danilov, MD

Dr. Danilov practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Danilov's NPI, 1487769733, was assigned on August 20, 2006. Dr. Danilov graduated from Yaroslavl Med Acad in 1997. Dr. Danilov's California license number on file is C166505.

Dr. Danilov's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Danilov's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Danilov to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Danilov practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Danilov's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Danilov is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Danilov's licenses on file in 4 states: California, Oregon, New Hampshire and Rhode Island.

Dmand AI lists chronic anemia, chronic leukemia, deep vein thrombosis (DVT) and lymphoma among the conditions Dr. Danilov treats.

CMS data shows 344 Medicare services from Dr. Danilov across 5 procedure codes in 2024, for 144 Medicare patients. Medicare paid $29,902 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 144 Medicare patients who saw Dr. Danilov in 2024. The largest group is 65 to 74, with 82 patients. 66% of them have high cholesterol, and 64% have high blood pressure. 17% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Danilov's median patient age at 71, with 42% women.

In 2024, Dr. Danilov wrote 202 Medicare Part D claims for 44 patients. 32% of them were for generic drugs. CMS names the drug for 132 of them, across 4 drugs with 11 or more claims each, at $1,269,693 in total drug cost. In 2023, CMS named 75 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Danilov for performance year 2024, reported as part of a group. Dr. Danilov accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Danilov as offering telehealth.

Dmand AI links 46 papers to Dr. Danilov, published from 2008 to 2025. 2025 was the busiest year, with 9. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Cell Line, Tumor and Apoptosis. Dr. Danilov has published most often in Mol Cancer Ther. Dr. Danilov's most frequent co-authors are Olga V. Danilova, MD, PhD, Geoffrey Shouse, DO, PhD and Matthew S. Davids, MD.

Dmand AI links Dr. Danilov to 8 clinical trials, 4 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Leukemia, Prolymphocytic, B-Cell, Lymphoma, Mantle-Cell and Leukemia, Prolymphocytic. City of Hope Medical Center sponsors the most, 7. Open Payments lists research payments to Dr. Danilov that name 2 trials.

CMS Open Payments shows 478 general payments to Dr. Danilov from 34 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. AstraZeneca Pharmaceuticals LP paid the most, $120,746. It also lists 5 research payments totaling $7,700 from 2020 to 2025, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Danilov, most recently Leukemia and Lymphoma Society Scholar in 2018.

Dr. Danilov graduated from Yaroslavl Med Acad in 1997.

Dr. Danilov is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.